In vitro metabolic stability of iiodinated obestatin peptides

Bart De Spiegeleer\textsuperscript{a,}\textsuperscript{*}, Sylvia Van Dorpe\textsuperscript{a}, Valentijn Vergote\textsuperscript{a}, Evelien Wynendaele\textsuperscript{a}, Ewald Pauwels\textsuperscript{b}, Christophe Van De Wiele\textsuperscript{c}, Pablo Garcia-Solis\textsuperscript{d}, Juan Carlos Solis-Sainz\textsuperscript{d}

\textsuperscript{a} Drug Quality and Registration (DruQuaR) Group, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, B-9000 Ghent, Belgium
\textsuperscript{b} Department of Subatomic and Radiation Physics, Faculty of Sciences, Ghent University, Ghent, Belgium
\textsuperscript{c} Department of Nuclear Medicine, Faculty of Medicine, Ghent University, De Pintelaan 185, B-9000 Ghent, Belgium
\textsuperscript{d} Department of Biomedical Research, Laboratory of Cellular and Molecular Physiology, School of Medicine, Autonomous University of Queretaro, Calle Clover 200, 76170 Queretaro, Mexico

\textbf{ARTICLE INFO}

Article history:
Received 14 November 2011
Received in revised form 18 December 2011
Accepted 18 December 2011
Available online 27 December 2011

Keywords:
Peptide iodination
\textit{In vitro} metabolic stability
Proteases
Deiodinases
Peptidomimetics

\textbf{ABSTRACT}

Different iiodinated mouse obestatin peptides have been characterized toward their \textit{in vitro} stability in the main metabolic compartments plasma, liver and kidney. Using HPLC–UV for quantification, significant differences in the degradation kinetics of the iodinated peptides, arising from both enzymatic proteolysis and dehalogenation, were found when compared to the native, unmodified peptide. HPLC–MS/MS analysis demonstrated that the cleavage sites were dependent upon the biological matrix and the location of the amino acid residue incorporating the iodine atom(s). The degrading proteases were found to target peptide bonds further away from the iodine incorporation, while proteolytic cleavages of nearby peptide bonds were more limited. Diiodinated amino acid residue containing peptides were found to be more susceptible to deiodination than the mono-iodinated derivative. In plasma, the percentage of peptide degradation solely attributed to deiodinase activity after 20 min incubation reached up to 25\% for 2,5-diiodo-H\textsuperscript{19}-obestatin compared to 20\% and only 3\% for (3,5-diido-Y\textsuperscript{16})- and (3-ido-Y\textsuperscript{16}) obestatin, respectively. Hence, our results demonstrate that the different iodinated peptides pose significantly different metabolicization properties and thus, also different biological activities are expected for peptides upon iodination.

© 2011 Elsevier Inc. All rights reserved.

1. Introduction

Obestatin is a recently discovered 23 amino acid peptide derived from the processing of the ghrelin gene, and has been claimed to be a functional opponent of ghrelin (suppressing food intake) making it a potential lead against obesity [32]. Although the \textit{in vivo} activity is increasingly being confirmed by a number of research groups [4,5,10,17,20], many also failed to show inhibitory effects on food and water intake [26]. Also, the underlying mechanism still remains unclear as demonstrated by numerous contradictory findings and a declaration by the discoverers of obestatin that even they cannot reproduce all their original findings without paying attention to e.g. specific (circadian) time-effects [31]. In attempts to explain the conflicting results on obestatin, several functional quality issues have been investigated in detail: presence of synthesis impurities in commercially available peptides [6] and formation of mixtures during radio-iodination [27,28]. As for most endogenous-derived peptide leads, obestatin has only little resistance to systemic plasma and tissue proteases [29] which may result in a failure to demonstrate convincing in \textit{vivo} effects [30]. The major \textit{in vitro} plasma metabolic pathways of m-obestatin have been shown to involve cleavage between residues F\textsuperscript{1}–N\textsuperscript{2} and P\textsuperscript{4}–E\textsuperscript{5}, with several other peptide bonds also being vulnerable to proteolytic activity (D\textsuperscript{9}–V\textsuperscript{7}, Y\textsuperscript{16}–Q\textsuperscript{17}, C\textsuperscript{20}–R\textsuperscript{21}, R\textsuperscript{21}–A\textsuperscript{22} and A\textsuperscript{22}–L\textsuperscript{23}). Currently, some recent studies investigated fragments or modified obestatin derivatives to provide protection against enzymatic degradation. Substitutions at G\textsuperscript{3} and G\textsuperscript{5} by \(\alpha\)-aminoisobutyric acid and at F\textsuperscript{5} by cyclohexylyalanine yielded promising insights into the structural requirements [19], while pegylated obestatin was found to be three times more stable than native obestatin [2]. Using the obestatin fragments (1–10) and (11–23), some structure–activity properties were defined [24]. The influence of obestatin on its functional behavior, of which the enzymatic degradation is an
important aspect, has not yet been described in detail for the different possible derivatives (i.e. mono- and diiodinated on Y\textsuperscript{16} and H\textsuperscript{19}), although these iodinated obestatines are used throughout biomedical studies. Moreover, the enzymatically catalyzed dehalogenation of iodinated peptides has not yet been investigated, despite its importance.

The aim of the present study was to investigate the effect of iodine incorporation at Y\textsuperscript{16} and H\textsuperscript{19} on the resistance of m-ostaatin against in vitro degradation in the main biological tissues (plasma, liver and kidney), encompassing proteolysis as well as deiodination. These data are not only important for the study of dehalogenation of peptides in general, but also for the generation of new peptidomimetics with improved stability characteristics and the interpretation of biomedical test results involving \textsuperscript{125}I-, \textsuperscript{123}I- or \textsuperscript{131}I-labeled peptides.

2. Materials and methods

2.1. Peptides and other materials

All peptides used (cf. Table 1) were of \geq 95.0% peptide purity, as verified by HPLC–UV analysis [6]. Unmodified mouse obestatin was obtained from California Peptide Research (Napa, CA, USA). Iodinated mouse obestatin derivatives (i.e. (3-iodo-Y\textsuperscript{16})-obestatin, (3,5-diiodo-Y\textsuperscript{16})-obestatin, (2,5-diido-H\textsuperscript{19})-obestatin and (3,5-diido-Y\textsuperscript{16}, 2,5-diido-H\textsuperscript{19})-obestatin; all prepared using Fmoc-chemistry) were purchased from Bachem (Bubendorf, Switzerland). Heparinized NMRI mouse plasma and male ICR CD-1 mice were obtained from Harlan (Horst, Netherlands); Modified Lowry Protein Assay Kit was purchased from Pierce Biotechnology (Rockford, IL, USA), and used according to the instructions of the supplier. All other reagents were of analytical grade or better.

The following relative area response factors were calculated for UV detection at 195/215 nm with reference to an equimolar quantity of the native obestatin: 1.08/1.59, 1.14/1.80, 1.00/1.18 and 1.11/1.77 for (3-iodo-Y\textsuperscript{16})-obestatin, (3,5-diiodo-Y\textsuperscript{16})-obestatin, (2,5-diido-H\textsuperscript{19})-obestatin and (3,5-diido-Y\textsuperscript{16}, 2,5-diido-H\textsuperscript{19})-obestatin, respectively. These values were used in the LC–UV kinetics.

2.2. Preparation of homogenates

After cervical dislocation, mouse organs were cleaned and transferred into ice-cold Krebs–Henseleit buffer pH 7.4 containing 0.2% (w/v) of d-glucose, followed by homogenization for approximately 1 min using a rotor–stator type homogenizer. After sedimentation for 30 min at 5 °C to remove the larger particles, the middle layer was taken as final homogenate, with aliquots stored at −35 °C until further use. Prior to use, the protein content of each homogenate was determined using the Pierce Modified Lowry Protein Assay method.

2.3. In vitro metabolic stability testing

In vitro metabolic stability testing was determined using previously described procedures [30]. In brief, 90 \textmu g of peptide was incubated in Krebs–Henseleit buffer pH 7.4 with plasma/tissue homogenate added (600 \textmu l of mouse plasma, 900 \textmu g of liver protein, or 300 \textmu g of kidney protein) at 37 °C while shaking. At predetermined time intervals, aliquots were immediately transferred into microtubes containing 1:10 volume of 1% (v/v) formic acid solution in water. The enzyme reaction was stopped by heating at 95 °C for 5 min. Next, the sample is centrifuged to precipitate the denatured proteins and collect the supernatant for subsequent HPLC analysis. Similarly, appropriate placebos, controls and reference solutions were prepared as well. Experiments were carried out in duplicates. Assuming first-order kinetics, the rate constant k was obtained from ln(P\textsubscript{i}/P\textsubscript{0}) = −kt, from which the metabolic half-life was determined as t\textsubscript{1/2} = ln(2)/k.

2.4. Liquid chromatography

The HPLC–PDA apparatus consisted of a Waters Alliance 2695 separations module, a Waters 2996 photodiode array detector and a Waters 2475 multi-wavelength fluorescence detector with Empower 2 software for data acquisition (all Waters, Milford, MA, USA). For PDA detection, the UV spectrum was recorded between 190 and 400 nm.

The HPLC–UV/MS apparatus consisted of a Spectra System SN4000 interface, a Spectra System SCM1000 degasser, a Spectra System P1000XR pump, a Spectra System AS3000 autosampler and a Finnigan LCQ Classic ion trap mass spectrometer in positive ion mode (all Thermo, San José, CA, USA) equipped with a Waters 2487 dual wavelength UV detector (Waters, Milford, MA, USA) and XCalibur 2.0 software (Thermo, San José, CA, USA) for data acquisition. From the total ion chromatogram (TIC), extracted ion chromatograms (EICs) were obtained at selected m/z values. Tandem mass spectrometry (MS/MS) data on obestatin peptides and their metabolites were examined using SEQUEST\textsuperscript{\textregistered} available in Bioworks 3.3.1 software (Thermo, San José, CA, USA) based upon a FASTA file containing the obestatin sequences.

HPLC analysis was performed using an Everest C\textsubscript{18} 238EV54 (250 mm × 4.6 mm I.D., 300 Å, 5 \mu m particle size) column (Grace Vydac, Hesperia, CA, USA) in an oven set at 30 °C, with the following solvent system: (A) 0.1% (w/v) formic acid in water, and (B) 0.1% (w/v) formic acid in acetonitrile. The gradient used for the separation was: 95% A + 5% B from 0 to 5 min, followed a linear ramp from 5 to 65 min going to 75% A + 25% B. The flow rate was set at 1.0 ml/min. The percentage of dehalogenation at the 20 min time point was estimated using the LC–MS data from the (diido)-, (monoiido)- and (noniido)-peptides, i.e. the non-proteolytic peptides only.

3. Results

Although iodine incorporation is considered to potentially hinder peptide breakdown by protease activity, a statistically significant (i.e. based upon the 95% confidence intervals) increase in half-life time was only observed for (3,5-diido-Y\textsuperscript{16})-obestatin in plasma and for (3-iido-Y\textsuperscript{16})-obestatin in liver homogenate (Fig. 1). The in vitro first-order degradation kinetic results obtained on the different iodinated obestatin derivatives in different biological matrices using UV detection at 195 nm are summarized in Table 2. Tetra-iodinated obestatin did not give consistent quantitative results due to excessive adsorption to containers and biological matrices. Several obestatin metabolites arising from proteolytic activity were observed using tandem mass spectrometry, being above the limit of detection of 0.02% relative to the parent peptide. Fig. 2 reflects the relative importance of the different peptides found, resulting from the cleavage of the indicated peptide bond compared to the total quantity of degradants. For non-iodinated mouse obestatin incubated in mouse plasma, liver and kidney (data not shown), the obtained proteolytic fragments were consistent with a previous study [29].

In addition to the proteolytic degradation, significant dehalogenation was observed for the iodinated derivatives, especially for (2,5-diido-H\textsuperscript{19})-obestatin incubated in plasma as depicted in Fig. 3. From Table 3, it is obvious that iodine atom(s) removal in plasma and liver homogenate increases in the following order: (3-iido-Y\textsuperscript{16})-, (3,5-diido-Y\textsuperscript{16})- and (2,5-diido-H\textsuperscript{19})-obestatin. The percentage of peptide degradation solely attributed to deiodinase activity after 20 min incubation reached up to 25.5% for
Table 1
Obestatin and its iodinated derivatives tested.

<table>
<thead>
<tr>
<th>#</th>
<th>Peptide</th>
<th>Sequence</th>
<th>M (g/mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Rat/mouse obestatin</td>
<td>FNAPFDVGIKLSGAQYQQHGRAL-NH₂</td>
<td>2516.82</td>
</tr>
<tr>
<td>2</td>
<td>(3-Iodo-Y₁⁰⁻)–obestatin</td>
<td>FNAPFDVGIKLSGAQ₁₂Y₅₁₉HGRAL-NH₂</td>
<td>2642.72</td>
</tr>
<tr>
<td>3</td>
<td>(3,5-Diiodo-Y₁⁰⁻)-obestatin</td>
<td>FNAPFDVGIKLSGAQ₁₂Y₅₁₉HGRAL-NH₂</td>
<td>2768.61</td>
</tr>
<tr>
<td>4</td>
<td>(2,5-Diiodo-H₁⁹⁻)-obestatin</td>
<td>FNAPFDVGIKLSGAQ₂₁₉HGRAL-NH₂</td>
<td>2768.61</td>
</tr>
<tr>
<td>5</td>
<td>(3,5-Diiodo-Y₁⁰⁻, 2,5-Diiodo-H₁⁹⁻)-obestatin</td>
<td>FNAPFDVGIKLSGAQ₂₁₉HGRAL-NH₂</td>
<td>3020.40</td>
</tr>
</tbody>
</table>

Fig. 1. Time-dependent decrease of native and mono-iodinated Y₁⁰⁻ mouse obestatin upon incubation in liver homogenate. Data are expressed as mean ± SEM.

Table 2
Half-life times of obestatin derivatives in biological matrices.

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Half-life (min) [95% C.I.]</th>
<th>Liver homogenate</th>
<th>Kidney homogenate</th>
</tr>
</thead>
<tbody>
<tr>
<td>(3,5-Diiodo-Y₁⁰⁻)-obestatin</td>
<td>26.9 [20.9, 37.9]</td>
<td>14.2 [10.1, 24.1]</td>
<td>18.8 [12.0, 43.6]</td>
</tr>
</tbody>
</table>

2,5-diiodo-H₁⁹⁻-obestatin in plasma, the remainder being proteolysis (34.5%) and intact peptide (40%). In liver, about half of the quantity of dehalogenation products were formed compared to plasma, attaining 11.2% for 2,5-diiodo-H₁⁹⁻-obestatin, together with 43.1% proteolytic fragments and 45.7% of the parent peptide. In vitro dehalogenation was also observed in kidney homogenate, although to a much lesser extent when compared to plasma and liver, being below 1%. However, because deiodination of proteolytic metabolites, nor proteolysis of deiodinated products, was taken into account, the percentage deiodination is actually underestimated. The conceptual scheme is visualized in Fig. 4. Especially when the percentage of deiodination was found to be rather high, several metabolites arising from a combination of dehalogenation and proteolysis were observed as well. This phenomenon is illustrated for (2,5-diiodo-H₁⁹⁻)-obestatin in mouse plasma, which was cleaved at the F₅–D₆ bond combined with the loss of a single iodine atom, yielding DVGIKLSGAQYQQHGRAL-NH₂. The total ion chromatogram demonstrated a retention time of 31.1 min for this proteolysis–dehalogenation product, showing three peaks in the mass spectrum with M + 2H²⁺ = 1033.9, M + 3H₃⁺ = 689.6 and M + 4H₄⁺ = 517.5. Its identity was further confirmed using the (tandem) mass spectrum (Fig. 5). This product may originate from two different pathways: (1) proteolysis of 2-iodo-H₁⁹⁻-obestatin (i.e. dehalogenation followed by proteolysis) or (2) deiodination of the F₅–D₆ metabolite fragment, which was first formed from (2,5-diiodo-H₁⁹⁻)-obestatin. Both in plasma and liver homogenate, the peptide bond between F₅ and D₆ was found to be more susceptible to proteolytic cleavage for the iodinated peptide

Table 3
Dehalogenation: non-/mono-/diiodinated obestatin area % at T₂₀th using HPLC–MS and percentage estimated.

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Plasma</th>
<th>Liver homogenate</th>
<th>Kidney homogenate</th>
</tr>
</thead>
<tbody>
<tr>
<td>(3-Iodo-Y₁⁰⁻)-obestatin</td>
<td>8.8/91.2/NA</td>
<td>2.6/97.4/NA</td>
<td>ND/100.0/NA</td>
</tr>
<tr>
<td>(3,5-Diiodo-Y₁⁰⁻)-obestatin</td>
<td>ND/24.1/75.9</td>
<td>0.5/7.9/91.6</td>
<td>ND/1.8/98.2</td>
</tr>
<tr>
<td>(2,5-Diiodo-H₁⁹⁻)-obestatin</td>
<td>18.9/20.2/60.9</td>
<td>0.3/19.4/80.3</td>
<td>ND/1.9/98.1</td>
</tr>
</tbody>
</table>

NA: not applicable; ND: not detectable as below the limit of detection, being 2.14 × 10⁻⁷%.
compared to the native peptide. In plasma, the relative importance of this cleavage compared to the total degradants rises from 2.5% in mouse obestatin to 23.5% for (3-iodo-Y16)-obestatin and further to about 49% and 34% in (3,5-diiodo-Y16)- and (2,5-diiodo-H19)-obestatin, respectively. Moreover, in plasma, the abundance of cleavages near the C-terminus of the sequence (i.e. L11→L23) was found to generally decrease upon peptide iodination, except for the R21→A22 bond, which actually increases upon iodination: 9.1% in unmodified obestatin to 30.8, 2.8 and 32.3% in the different iodinated derivatives. In liver, a similar effect was observed, together with an inhibition decrease upon peptide iodination, except for the R21→A22 bond, which actually increases upon iodination: 9.1% in unmodified obestatin to 30.8, 2.8 and 32.3% in the different iodinated derivatives. The observed deiodination of obestatin was the result of an enzymatic catalysis, and thus not driven, since the chemical control (i.e. incubation of peptide in buffer) did not reveal any presence of deiodinated nor oxidated obestatin peptides. Moreover, in the tissue metabolism samples, no oxidative deiodination products could be observed using EIC-LC–MS.

4. Discussion

Upon comparison of the in vitro stability of mouse obestatin and its iodinated derivatives in different biological media, cleavage by proteolytic enzymes was found to be less pronounced for the iodinated peptide. The main enzymes responsible for the production of the metabolites were found to be pepsin, proteinase K, chymotrypsin and thermolysin, belonging to the pepsin A1 family, subtilisin S8, trypsin S1 family and thermolysin M4 family, respectively [1,22]. The first three enzymes prefer to cleave after aromatic

Fig. 2. Graphical overview of the proteolytic cleavages observed in plasma and liver homogenate. The relative importance was based on the total amount metabolites observed and subdivided in four classes: (1) below the limit of quantification (i.e. LoQ=0.07%), (2) between LoQ and 10%, (3) between 10–30%, and (4) above 30%.

Plasma

| mOb: F | N | A | P | F | D | V | G | I | K | L | S | G | A | Q | Y | Q | Q | H | G | R | A | L | NH₂ |
| I₁YmOb: F | N | A | P | F | D | V | G | I | K | L | S | G | A | Q | I₁Y | Q | Q | H | G | R | A | L | NH₂ |
| I₂YmOb: F | N | A | P | F | D | V | G | I | K | L | S | G | A | Q | I₂Y | Q | Q | H | G | R | A | L | NH₂ |
| I₃YmOb: F | N | A | P | F | D | V | G | I | K | L | S | G | A | Q | I₃Y | Q | Q | H | G | R | A | L | NH₂ |
| I₄YmOb: F | N | A | P | F | D | V | G | I | K | L | S | G | A | Q | I₄Y | Q | Q | H | G | R | A | L | NH₂ |

Liver homogenate

| mOb: F | N | A | P | F | D | V | G | I | K | L | S | G | A | Q | Y | Q | Q | H | G | R | A | L | NH₂ |
| I₁YmOb: F | N | A | P | F | D | V | G | I | K | L | S | G | A | Q | I₁Y | Q | Q | H | G | R | A | L | NH₂ |
| I₂YmOb: F | N | A | P | F | D | V | G | I | K | L | S | G | A | Q | I₂Y | Q | Q | H | G | R | A | L | NH₂ |
| I₃YmOb: F | N | A | P | F | D | V | G | I | K | L | S | G | A | Q | I₃Y | Q | Q | H | G | R | A | L | NH₂ |
| I₄YmOb: F | N | A | P | F | D | V | G | I | K | L | S | G | A | Q | I₄Y | Q | Q | H | G | R | A | L | NH₂ |
amino acids (e.g. Y, W or F) which fit in the hydrophobic pocket of the enzyme. Other amino acids are targeted as well, but at a much lower rate.

Apparently, the relevant proteases are negatively influenced in their catalytic hydrolysis by the supplementary iodine atom(s), but this protease inhibition was compensated by additional dehalogenase activity. This latter phenomenon was found to be mainly associated with plasma and liver, and more strongly affecting the two diiodinated peptides. Our findings show that the diiodotyrosine amino acid residue is more susceptible to dehalogenation than monoiodo-tyrosine, independent of the biological matrix. Moreover, (2,5-diiodo-H\textsuperscript{19})-obestatin was more rapidly dehalogenated compared to (3,5-diiodo-Y\textsuperscript{16})-obestatin.

The presence of such diiodinated species upon obestatin radioiodination may thus give rise to erroneous or even false negative results when used for certain \textit{in vitro} (e.g. receptor binding) and \textit{in vivo} (e.g. distribution/imaging, blood–brain–barrier transport, metabolic stability) studies.

Iodine, a scarce micronutrient, is actively salvaged in vertebrates from metabolized compounds for the biosynthesis of thyroid hormones which are essential for normal brain development, growth and metabolism \cite{16}. Enzymatic deiodination of mono- and diiodinated tyrosine and histidine amino acids (MIT, DIT, MIH and D IH, respectively) has been reported to occur both \textit{in vitro} and \textit{in vivo} \cite{8,23}, with excretion of these iodinated compounds being indicative for certain thyroidal disorders \cite{9,16}. To our best knowledge, no direct measurement of \textit{in vitro} peptide deiodination, yielding extensive sequence information on the metabolites formed has been published yet. Dehalogenation of MIT by thyroid iodothyrosine deiodinase (IYD) was reported to be faster than that of DIT \cite{23}, and requires a bound flavin mononucleotide (FMN) for its catalytic activity. In contrast, iodothyronine deiodinase (ID or DI) requires an active-site Cys for reduced thyroxine generation \cite{7}. These enzymes represent the most common two currently known reductive dehalogenation pathways in mammals (Fig. 6), while cytochrome systems were also described to dehalogenate in an oxidative way \cite{3,11,12,14}. This latter enzyme was found not to be responsible for the deiodination of obestatin derivatives because no oxidated fragments were observed in the mass spectra of our samples. When comparing the substrate specificity of IYD to our results on peptide-incorporated iodotyrosines, we demonstrated just the opposite: a larger fraction dehalogenation of diiodo-tyrosine iodinated peptide is obtained compared to that of monoiodo-tyrosine iodinated peptide. This latter finding is thus not only considered to be more consistent with an efficient salvage of iodine atoms, but would also require another enzyme. Furthermore, the conformation of the IYD active site accommodating MIT and DIT is not likely to allow for additional amino acid residues in the pocket surrounding the substrate and FMN as it is stated that there is little or no access possible for solvents \cite{25}. Type I iodothyronine 5′-deiodinase (ID1) presents a broader substrate specificity with a preference l-thyroxine (T\textsubscript{4}) \textgtrsim 3,3′,5-triiodothyronine (T\textsubscript{3}) \cite{15}, which is more consistent with our data. The evaluation of the currently known enzymes being possibly the major responsible for the deiodination of obestatin reveals future perspectives, which we are currently investigating.

Although a significantly decreased enzymatic degradation with a more than doubling of its half-life (from 15.7 to 41.5 min) is observed for mono-iodinated obestatin in liver homogenate when compared to the native peptide, it is not predictable whether or not this compound will exhibit either an increased or decreased activity: e.g. inactivation by antibodies \cite{21} and altered affinity for its receptor \cite{13,18}. In addition to proteolysis or dehalogenation solely, we also demonstrated the occurrence of combinations of dehalogenated metabolites or metabolized dehalogenated peptides. As visualized in our scheme (Fig. 4) and confirmed in our data, deiodination and enzymatic proteolysis processes both occur. Since these dehalogenated proteolytic fragments were not taken into account in the estimation of the percentage dehalogenation, the actual dehalogenated fraction is even higher than our data.

In conclusion, this study demonstrated that the pharmacokinetic profile of tyrosine- and histidine-iodinated mouse obestatin derivatives is not only severely compromised through rapid
Fig. 5. Tandem MS spectrum of the F5-D6 cleavage and single deiodination product (DVGIKLSCAQLIQGRAL-NH2), eluting at 31.1 min, with a selected parent m/z value of 689.48. This metabolite arises from both proteolysis and dehalogenation as observed after incubation of (2,5-diiodo-H19)-obestatin during 20 min in mouse plasma.

Fig. 6. Enzymatic reductive dehalogenation pathways.

degradation by systemic proteolytic enzymes, but also by dehalogenases. Also, the site-specificity of the proteases is altered by incorporation of iodine atoms. Hence, their use to directly predict the in vivo pharmacokinetics of unmodified peptide is questionable.

Acknowledgements

This work was supported by the Flemish Institute supporting Scientific-Technological Research in Industry (IWT grant 073402 to S.V.D.) and through the “Functional Peptidomics project” (IWT grant SBO-050164 to V.V. and B.D.S.). Support by the Special Research Fund of Ghent University (01J22510) is acknowledged by E.W. and B.D.S. The authors thank Nadia Lemeire for technical assistance.

Appendix A. Supplementary data


References


